The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jun. 23, 2015

Filed:

Apr. 27, 2012
Applicants:

Jeffrey A. Robl, Newtown, PA (US);

Jun LI, Princeton, NJ (US);

Lawrence J. Kennedy, Titusville, NJ (US);

Steven J. Walker, Pennington, NJ (US);

Haixia Wang, Columbus, NJ (US);

William N. Washburn, Titusville, NJ (US);

Saleem Ahmad, Wall, NJ (US);

Khehyong Ngu, Pennington, NJ (US);

Inventors:

Jeffrey A. Robl, Newtown, PA (US);

Jun Li, Princeton, NJ (US);

Lawrence J. Kennedy, Titusville, NJ (US);

Steven J. Walker, Pennington, NJ (US);

Haixia Wang, Columbus, NJ (US);

William N. Washburn, Titusville, NJ (US);

Saleem Ahmad, Wall, NJ (US);

Khehyong Ngu, Pennington, NJ (US);

Assignee:

Bristol-Myers Squibb Company, Princeton, NJ (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07D 401/04 (2006.01); C07D 401/14 (2006.01); C07D 403/04 (2006.01); C07D 413/04 (2006.01); C07D 413/14 (2006.01); A61K 31/47 (2006.01); A61K 31/4709 (2006.01); A61K 31/473 (2006.01); C07D 215/08 (2006.01); C07D 417/04 (2006.01); A61K 31/4747 (2006.01); A61K 31/496 (2006.01); A61K 31/506 (2006.01); A61K 31/5377 (2006.01); A61K 31/5415 (2006.01); A61K 31/55 (2006.01); A61K 31/553 (2006.01); A61K 31/554 (2006.01); A61K 31/675 (2006.01); A61K 45/06 (2006.01); C07D 221/16 (2006.01); C07D 401/12 (2006.01); C07D 405/14 (2006.01); C07D 409/14 (2006.01); C07F 9/60 (2006.01);
U.S. Cl.
CPC ...
C07D 401/04 (2013.01); C07D 215/08 (2013.01); C07D 401/14 (2013.01); C07D 403/04 (2013.01); C07D 413/04 (2013.01); C07D 413/14 (2013.01); C07D 417/04 (2013.01); A61K 31/47 (2013.01); A61K 31/4709 (2013.01); A61K 31/473 (2013.01); A61K 31/4747 (2013.01); A61K 31/496 (2013.01); A61K 31/506 (2013.01); A61K 31/5377 (2013.01); A61K 31/5415 (2013.01); A61K 31/55 (2013.01); A61K 31/553 (2013.01); A61K 31/554 (2013.01); A61K 31/675 (2013.01); A61K 45/06 (2013.01); C07D 221/16 (2013.01); C07D 401/12 (2013.01); C07D 405/14 (2013.01); C07D 409/14 (2013.01); C07F 9/60 (2013.01);
Abstract

Novel compounds of Formula I:or an enantiomer, diastereomer, tautomer, prodrug or salt thereof, wherein m, Q, T, U, V, ring A, X, Y, R, R, R, R, R, R, R, R, R, R, and Rare defined herein, are provided which are TGR5 G protein-coupled receptor modulators. TGR5 G protein-coupled receptor modulators are useful in treating, preventing, or slowing the progression of diseases requiring TGR5 G protein-coupled receptor modulator therapy. Thus, the disclosure also concerns compositions comprising these novel compounds and methods of treating diseases or conditions related to the activity of the TGR5 G protein-coupled receptor by using any of these novel compounds or a composition comprising any of such novel compounds.


Find Patent Forward Citations

Loading…